Alistair Duncan
Oprichter bij viDA Therapeutics, Inc.
Profiel
Alistair Duncan is the founder of Chromos Molecular Systems, Inc. (founded in 1998) and.
viDA Therapeutics, Inc. (founded in 2008).
He holds the title of President & Chief Executive Officer at Chromos Molecular Systems, Inc. in 2008 and President, Chief Executive Officer & Director at viDA Therapeutics, Inc. He is currently a Director at Metro Vancouver Properties Corp.
Mr. Duncan previously worked as a Director at MIGENIX, Inc. from 2004 to 2010, Director at Global Gaming Technologies Corp.
from 2010 to 2012, and Director at BC Technology Industry Association and Michael Smith Foundation for Health Research.
He also held the position of Principal at Ernst & Young LLP, Chief Financial Officer at Agrisoma Biosciences, Inc., and was a Member of The Institute of Chartered Accountants of British Columbia.
Mr. Duncan completed his undergraduate degree at the University of British Columbia.
Actieve functies van Alistair Duncan
| Bedrijven | Functie | Begin |
|---|---|---|
viDA Therapeutics, Inc.
 viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Oprichter | 01-01-2008 |
Eerdere bekende functies van Alistair Duncan
| Bedrijven | Functie | Einde |
|---|---|---|
| The Institute of Chartered Accountants of British Columbia | Corporate Officer/Principal | 22-10-2012 |
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | 24-03-2010 |
Chromos Molecular Systems, Inc.
 Chromos Molecular Systems, Inc. BiotechnologyHealth Technology Chromos is a cellular engineering and therapeutics company creating value through engineering production quality cell lines for the manufacture of biopharmaceuticals, and developing innovative therapies for infectious diseases, cancer and genetic disorders. Chromos is achieving these objectives with its ACE System (Artificial Chromosome Expression) and REM (Rapid Expansion Method) technologies. In the near term, Chromos will focus on continued commercialization of the ACE System for engineering cell lines. To date Chromos has entered into corporate partnerships related to cell line engineering with partners including Pfizer Inc., Centocor, Inc. and Cambridge Antibody Technology | Oprichter | 16-04-2008 |
| GLOBAL GAMING TECHNOLOGIES CORP. | Directeur/Bestuurslid | - |
Opleiding van Alistair Duncan
| University of British Columbia | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GLOBAL GAMING TECHNOLOGIES CORP. | Finance |
| Bedrijven in privébezit | 7 |
|---|---|
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
Michael Smith Foundation for Health Research
 Michael Smith Foundation for Health Research Investment Trusts/Mutual FundsMiscellaneous The Michael Smith Foundation for Health Research operates as a health research funding agency. The non-profit company is based in Vancouver, Canada. Diane Finegood has been the CEO of the Canadian company since 2012. | Miscellaneous |
| BC Technology Industry Association | |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Health Technology |
Chromos Molecular Systems, Inc.
Chromos Molecular Systems, Inc. BiotechnologyHealth Technology Chromos is a cellular engineering and therapeutics company creating value through engineering production quality cell lines for the manufacture of biopharmaceuticals, and developing innovative therapies for infectious diseases, cancer and genetic disorders. Chromos is achieving these objectives with its ACE System (Artificial Chromosome Expression) and REM (Rapid Expansion Method) technologies. In the near term, Chromos will focus on continued commercialization of the ACE System for engineering cell lines. To date Chromos has entered into corporate partnerships related to cell line engineering with partners including Pfizer Inc., Centocor, Inc. and Cambridge Antibody Technology | Health Technology |
| The Institute of Chartered Accountants of British Columbia | Commercial Services |